MetaCap

Apyx Medical (APYX) vs Pulmonx (LUNG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pulmonx (LUNG) has outperformed Apyx Medical (APYX) over the past year, gaining 78.5% versus a loss of 40.0%. Over five years, APYX leads with a -83.4% price change compared with -92.4% for LUNG. Pulmonx is the larger company by market cap ($111.9 million vs $101.1 million), about 1.1 times the size, while Apyx Medical is growing revenue faster (+9.9% vs +8.0%).

Apyx Medical converts more of its revenue into profit, with a net margin of -21.2% versus -59.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APYX-40.00%LUNG+78.47%
+128%+39%-49%
Nov 21, 20251 yearNov 20, 2026
APYX-85.69%LUNG-92.59%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APYX versus LUNG key metrics
MetricAPYXLUNG
Share price$2.40$2.57
Market cap$101.10M$111.93M
1-day change+0.42%-6.20%
YTD return-31.43%+16.29%
1-year return-40.00%+78.47%
5-year return-83.40%-92.39%
EPS (TTM)$-0.19$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$52.84M$90.50M
Revenue growth (YoY)+9.86%+8.01%
Net income (latest FY)$-11.21M$-54.00M
Gross margin62.53%74.19%
Operating margin-12.20%-59.30%
Net margin-21.22%-59.67%
52-week high$5.08$3.25
52-week low$2.25$1.13
Distance from 52-week high-52.76%-20.92%
Analyst consensusstrong_buynone
Avg. price target upside+170.83%+65.37%
Average volume146.81K641.52K
Shares outstanding42.12M43.55M
Employees205296
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LUNG has outperformed APYX by 118.5 percentage points over the past year.
  • Apyx Medical is more profitable, keeping -21.2 cents of every revenue dollar as net income versus -59.7 cents for Pulmonx.

About Apyx Medical

APYX stock →

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).

Health Care · Medical/Dental Instruments · 205 employees

About Pulmonx

LUNG stock →

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

Health Care · Medical/Dental Instruments · 296 employees

APYX vs LUNG FAQ

Which is bigger, Apyx Medical or Pulmonx?

Pulmonx (LUNG) is larger, with a market capitalization of $111.93M compared with $101.10M for Apyx Medical (APYX).

Which stock has performed better over the past year, APYX or LUNG?

LUNG returned +78.47% over the past 12 months, compared with -40.00% for APYX (price return, excluding dividends). Past performance does not predict future results.

Are Apyx Medical and Pulmonx in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons